Compare SFST & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | STRO |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 524.8M |
| IPO Year | 2012 | N/A |
| Metric | SFST | STRO |
|---|---|---|
| Price | $58.03 | $29.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $64.00 | $31.33 |
| AVG Volume (30 Days) | 113.7K | ★ 281.6K |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $6,282,000.00 | N/A |
| Revenue This Year | $10.47 | N/A |
| Revenue Next Year | $12.19 | N/A |
| P/E Ratio | $49.14 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $35.36 | $0.67 |
| 52 Week High | $62.38 | $43.85 |
| Indicator | SFST | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 50.77 |
| Support Level | $53.96 | $23.53 |
| Resistance Level | $58.43 | $30.94 |
| Average True Range (ATR) | 1.91 | 2.89 |
| MACD | -0.16 | 0.40 |
| Stochastic Oscillator | 30.83 | 76.63 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.